Form 4 for IMVT Immunovant, Inc.
Accepted 2021-08-02 00:00:00 ET · period of report 2021-08-02 · accession 0001104659-21-099083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-02 | 2021-08-02 | IMVT | Roivant Sciences Ltd. | 10% | J - Other | — | +17.02M | 73.39M | +30% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.0001 par value per share | 2021-08-02 | J | A | 17,021,276 | — | 73,388,664 | D | — | — | (F1) On August 2, 2021, Roivant and Immunovant, Inc. ("Immunovant") entered into a Share Purchase Agreement pursuant to which Roivant purchased 17,021,276 shares of Immunovant's common stock for an aggregate purchase price of $200,000,000, in cash, representing a per share price of $11.75. |